Novo’s H1 Exceeds Estimates On GLP-1, Obesity Sales Performance
Full-Year Guidance Raised Again With Wegovy Factored In
The company’s semaglutide franchise pushed net sales for the first half of 2021 up 5% year over year at DKK66.8bn ($10.6bn), helped by double- and triple-digit growth for Ozempic and Rybelsus.
You may also be interested in...
Novo Nordisk’s obesity product sales have soared against the odds as supply chain issues for recently approved Wegovy continued.
Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.
With US FDA approval for Saxenda (liraglutide) Novo Nordisk could be a contender in the market for prescription weight loss drugs, which so far has yielded disappointing sales from oral obesity therapies approved in the US since 2012 starting with Belviq (lorcaserin) from Arena Pharmaceuticals.